Injectable Drug Market

Injectable drug sales will expand through 2036, with monoclonal antibodies at 25.2% within the product type segment, intravenous administration at 48.3% of the route of administration category and oncology at 33% of application demand in 2026. The market is projected to record a 5.8% CAGR between 2026 and 2036.